Table 6 Summary of the reported lumefantrine AUC and elimination half-life
Study ID | Statistics | HIV-uninfected group | TS prophylaxis | NVP | EFV | LPV/r | ATV/r | PLHIV not yet on ART |
|---|---|---|---|---|---|---|---|---|
Lumefantrine half-life (h) | ||||||||
 10 | Mean (95%CI) |  | 36.0 (34.1–37.9) | 33.3 (30.9–35.7) | 33.3 (30.9–35.7) |  |  |  |
 11 | Median (IQR) |  |  | 63.4 (46.8–111.1) | 23.7 (21.8–46.0) | 98.7 (88.4–119.1) | 64.3 (52.0–120.6) | |
 13 | Mean (SEM) | 31.16 (1.86) |  |  |  |  | 42.59 (3.77) |  |
 15 | GM (90%CI) |  |  |  | 59.2 (46.7–75.1) |  |  | 89.5 (75.3–106.3) |
Lumefantrine AUC (ng.h/ml) | ||||||||
 21 | Median (IQR), AUC0-∞ |  |  | 977,645 (688,477–1,383,975) | 303,130 (211,080–431,962) |  |  | 784,830 (547,405–1,116,250) |
 10 | Mean (95%CI) AUC0-∞ |  | 375,200 (349,700–400,700) | 264,800 (243,100–286,500) | 264,800 (243,100–286,500) |  |  |  |
 11 | GM (90%CI), AUC0-∞ |  |  | 278,000 (228,000–339,000) | 130,000 (107,000–157,000) | 579,000 (477,000–704,000) |  | 270,000 (232,000–313,000) |
 13 | Mean (SEM), AUC0–168 | 447,976 (± 80,887) |  |  |  |  | 670,530 (± 157,173) |  |
 15 | GM (90%CI), AUC0-∞ |  |  |  | 188 (125–281) |  |  | 287 (237–349) |
 16 | Mean (SEM), AUC0–168 | 83,508 (± 5361) |  | 125,285 (± 35,221) | 58,396 (± 8019) | 357,295 (± 5156) |  |  |